ProPhase Labs, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74345W1080
USD
0.14
0 (-0.71%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About ProPhase Labs, Inc. stock-summary
stock-summary
ProPhase Labs, Inc.
Pharmaceuticals & Biotechnology
ProPhase Labs, Inc. manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company's products include TK Supplements and ORXx Complete. TK Supplements consists of LEGENDZ XL, a male sexual enhancement; TRIPLE EDGE XL, a daily energy and stamina booster, and SUPER PROSTAFLOW plus, a supplement to support prostate and urinary health. The Company's OTC offerings include the ORXx cough/cold drops. Its consumer health customers include national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.
Company Coordinates stock-summary
Company Details
711 STEWART AVENUE, GARDEN CITY , NEW YORK NY : 11530
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (4.46%)

Foreign Institutions

Held by 9 Foreign Institutions (0.56%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Ted Karkus
Chairman of the Board, Chief Executive Officer
Mr. Jason Barr
Independent Director
Dr. Louis Gleckel
Independent Director
Mr. Warren Hirsch
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 21 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.51

stock-summary
Return on Equity

-189.87%

stock-summary
Price to Book

1.81